Parabilis Medicines, Inc. (PBLS)
40.42
-0.33
(-0.81%)
USD |
NASDAQ |
Sep 04, 16:00
40.42
0.00 (0.00%)
Pre-Market: 20:00
Parabilis Medicines Research and Development Expense (Quarterly) : 39.38M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 39.38M |
| March 31, 2026 | 37.65M |
| Date | Value |
|---|---|
| June 30, 2025 | 30.13M |
| March 31, 2025 | 33.80M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Moderna, Inc. | 588.00M |
| Kailera Therapeutics, Inc. | 101.06M |
| Arrowhead Pharmaceuticals, Inc. | 192.06M |
| Oncolytics Biotech, Inc. | 4.262M |
| Sangamo Therapeutics, Inc. | 26.57M |